Page 431 - شرور شركات الأدوية

‫ﻣﻼﺣﻈﺎت‬

(62) Spingarn RW, Berlin JA, Strom BL. When pharmaceutical manu-
facturers’ employees present grand rounds, what do residents remember?
Acad Med. 1996 Jan;71(1):86–8.

(63) Wazana A. Physicians and the Pharmaceutical Industry: Is a Gift
Ever Just a Gift? JAMA. 2000 Jan 19;283(3):373–80.

(64) Lurie N, Rich EC, Simpson DE, Meyer J, Schiedermayer DL, Good-
man JL, et al. Pharmaceutical representatives in academic medical cen-
ters: interaction with faculty and housestaff. J Gen Intern Med. 1990
Jun;5(3):240–3.

(65) Fugh-Berman A, Ahari S. Following the Script: How Drug Reps
Make Friends and Influence Doctors. PLoS Med. 2007 Apr;4(4).

(66) Ibid.
(67) Sismondo S. How pharmaceutical industry funding affects trial
outcomes: Causal structures and responses. Social Science & Medicine.
2008;66(9):1909–14.
(68) Completed Cases—PMCPA Website [Internet]. [cited 2012 Mar 26].
Available from: http://www.pmcpa.org.uk/?q=node/868.
(69) Completed Cases—PMCPA Website [Internet]. [cited 2012 Mar 26].
Available from: http://www.pmcpa.org.uk/?q=node/883.
(70) Orlowski JP, Wateska L. The effects of pharmaceutical firm entice-
ments on physician prescribing patterns. There’s no such thing as a free
lunch. Chest. 1992 Jul;102(1):270–3.
(71) Steinbrook R. For sale: physicians’ prescribing data. N. Engl. J. Med.
2006 Jun 29;354(26):2745–7.
(72) Physician Data Restriction Program (PDRP) [Internet]. [cited
2012 Mar 22]. Available from: http://www.ama-assn.org/ama/pub/
about-ama/physician-data-resources/ama-database-licensing/amas-
physician-data-restriction-program.page.

431